.4B, trading at NT$70.90 on the TWO. This SniperIQ fundamentals page covers ICARES Medicus's valuation (P/E 79.7x, P/B 1.1x), profitability (net margin -0.5%), revenue (NT

What is ICARES Medicus's P/E ratio?

ICARES Medicus's trailing twelve-month P/E ratio is 79.7x, with a price-to-book (P/B) of 1.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is ICARES Medicus?

ICARES Medicus runs a net profit margin of -0.5%, a gross margin of 58.5%, and an operating margin of 9.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does ICARES Medicus generate?

ICARES Medicus reported revenue of NT

M and earnings per share (EPS) of 1.09. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does ICARES Medicus pay a dividend?

ICARES Medicus offers a trailing dividend yield of about 0.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is ICARES Medicus financially healthy?

ICARES Medicus carries a debt-to-equity ratio of 0.45x and a current ratio of 2.07x, with a market beta of 0.28. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is ICARES Medicus a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For ICARES Medicus (6612) the key facts are: market cap NT

.4B, P/E 79.7x, revenue NT

Track ICARES Medicus's full fundamentals live

Get ICARES Medicus's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.